Skip to content
USPeptideRxLearnApply for an account

Operator Q&A

Is office-use compounding legal?

USPeptideRx EditorialLast reviewed:

It depends on the state and on federal law, and among the states this page covers the answer is more often no than yes. Illinois and North Carolina permit human office use as a matter of state pharmacy law — Illinois only for non-sterile preparations — while Georgia and New Jersey prohibit it, Louisiana authorises a veterinary pathway only, and Ohio’s position is contested.

The short answer, state by state

StateHuman office use from a 503A pharmacy
GeorgiaProhibited — the rule says "is prohibited"
New JerseyProhibited, sterile and non-sterile
LouisianaNot authorised; the only lane is veterinary
OhioNarrow and legally contested
IllinoisPermitted, non-sterile only; sterile prohibited
North CarolinaPermitted under state pharmacy law, conditioned on federal law

Quantity caps, label legends, recordkeeping duties and the verbatim rule text for each are in the state-by-state office-use guide.

Why "permitted" rarely means permitted, full stop

North Carolina, Louisiana, New Jersey and Ohio each hand the question back to federal law, and 21 U.S.C. § 353a exempts a compounded drug from federal approval requirements only when it is compounded for an identified individual patient against a valid prescription order. North Carolina is the clearest example, and it is also the state most often cited as permissive:

(c) A pharmacy may supply compounded drug products to practitioners authorized by law to prescribe drugs for those practitioners to administer to those practitioners' patients. Such compounding for office use shall comply with applicable federal law.

The second sentence is the whole question. North Carolina permits office use as a matter of state pharmacy law; it does not create a federal safe harbour. New Jersey's prohibition carries the same structure in reverse, barring the practice "except to the extent permitted by Federal law." Ohio's rule simply commands compliance with § 353a. Louisiana's board says it outright in its veterinary provision: "the board's rules cannot legitimize an activity that is not permitted under federal law or rule."

Where the one clear lane is

Illinois, for non-sterile preparations, and conditional even there. A pharmacist may deliver a "reasonable quantity" of a non-sterile compounded drug for office use, bounded by the beyond-use date, by what is reasonable for the practice, and by what the pharmacy can compound to standard across all practitioners it serves. Records naming the practitioner, quantity, lot number and beyond-use date are kept five years, and every container carries the legend "For Office Use Only Not for Resale." Sterile office use is prohibited outright unless the pharmacy is a registered 503B outsourcing facility and an Illinois wholesale drug distributor.

How to check a state that is not on this list

Read your own board of pharmacy's compounding rule, specifically the subsection on office use or non-patient-specific distribution, and check whether it conditions the permission on federal law. Then ask any supplier for the citation behind its answer rather than a summary of it. If the question you are actually asking is a purchasing one rather than a legal one, can a med spa stock compounded drugs? works the same rules from the buyer's side. Two narrower versions of this question have their own answers: whether a nurse practitioner can order from a compounding pharmacy turns on state prescriptive authority rather than on the compounding rule, and ordering for patients in another state adds the receiving state's nonresident licensure to whatever your own state allows. Two of these verdicts are routinely reported backwards: Georgia's rule says office use "is prohibited" in those words, and North Carolina's permission is expressly conditioned on compliance with applicable federal law — so neither state is the open door it is often described as. The term itself, and the exclusion that decides which deliveries it covers at all, is defined at office use.

What this page does not establish

  • This page states the position in Georgia, North Carolina, Ohio, Louisiana, New Jersey and Illinois, each read in full from primary sources. A state not named here is unknown on this page — not permissive and not prohibited — and no answer here should be extrapolated to it.
  • This page states the verdicts and links to the rule text; it is not a substitute for reading your own state’s compounding rule.
  • The New Jersey rule text is verified current as of a January 2025 capture and is self-dated May 2024. A later revision has not been ruled out.
  • No Board guidance reconciling Ohio’s statute with its § 353a rule was found. The effective dates its Rule Tracker and guidance document give for the compounding-reference rule are not in conflict — February 28, 2026 is a prior effective date and June 1, 2026 a later amendment, both carried on the rule itself — and the Board’s February 28, 2027 enforcement delay is separate from both.
  • Nothing here describes any drug’s safety or effectiveness.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.

  1. [1]21 U.S.C. § 353a — Pharmacy compounding (Cornell LII)
  2. [2]Ga. Comp. R. & Regs. r. 480-11-.02(1)(d) — Pharmaceutical Compounding
  3. [3]21 NCAC 46 .2801(c) — North Carolina Board of Pharmacy rules
  4. [4]Ohio Admin. Code 4729:7-2-03(E) — compliance with 21 U.S.C. § 353a
  5. [5]La. Admin. Code tit. 46, pt. LIII, § 2535 — Compounding of Drugs
  6. [6]N.J.A.C. 13:39-11.18 and 13:39-11A.6 — State Board of Pharmacy (archived capture, 2025-01-21)
  7. [7]68 Ill. Adm. Code 1330.640 — Pharmaceutical Compounding Standards